Evommune's EVO756 flops in Phase 2b eczema trial, its second mid-stage miss this summer; MRGPRX2 drug's migraine study continues.
Evommune’s Dermira-derived small molecule has failed a Phase 2b test in atopic dermatitis, marking the second mid-stage flop for the experimental …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Evommune halts EVO756 development in atopic dermatitis following a Phase 2b trial failure, shifting focus to its EVO301 candidate.
Evommune said EVO756 failed to meet the primary endpoint in a Phase 2b CSU trial, ending development in the indication.
Evommune shares fell more than 30% on Monday morning after the biotech reported its first major trial readout since going public…
Evommune, Inc. (EVMN) Securities Fraud Investigation - Levi & Korsinsky
Clear Street lowered the firm’s price target on Evommune (EVMN) to $23 from $28 and keeps a Buy rating on the shares. The firm…
The company made the announcement after a new round of research results bolstered the case for the experimental medicine, which…
